Could Gilead's COVID-19 Drug Make $7 Billion Per Year?

SVB Leerink analyst Geoffrey Porges has changed his mind about Gilead Sciences' (NASDAQ:GILD) COVID-19 drug, remdesivir. Less than six weeks ago, he wrote to clients that remdesivir had "limited economic value to the company and the stock." Now, though, Porges thinks Gilead's COVID-19 treatment could be a tremendous commercial success.